Loading institutional data...
Loading institutional data...
Insufficient data to determine institutional momentum.
Data as of Q2 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading analysis...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $10K buybacks = $10K returned on -$5.9M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A cash-return story — far more went to shareholders than back into the business (mature, low-reinvestment).
Insufficient data. Current ROIC on all capital: -80%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $14K is below the $393K due within a year — relies on refinancing or operating cash flow. Scheduled principal only (excludes interest & revolver draws). As of 2017-12-31 (10-K).
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Interest last disclosed in FY2021 (no longer broken out).
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
Top 13 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow on any basis, so a reverse DCF can't be run.
EOD close · as of 2026-10-05
How a revenue dollar becomes profit — FY2025
Dividends and buybacks are cash paid out, shown here against the same year's profit for scale — not funded from it.
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6K 100.0% | $11K 100.0% | $9K 100.0% | $89K 100.0% | $88K 100.0% | $165K 100.0% | $166K 100.0% | $124K 100.0% | $5K 100.0% | $0 |
| Cost of Revenue | $2K 36.6% | $4K 40.0% | $4K 40.0% | $28K 32.2% | $48K 54.6% | $51K 30.8% | $45K 27.5% | $70K 56.6% | $8K 166.7% | $0 |
| Gross Profit | $4K 63.4% | $7K 60.0% | $5K 60.0% | $60K 67.8% | $40K 45.4% | $114K 69.2% | $120K 72.5% | $54K 43.4% | -$3K -66.7% | $0 |
| Research & Development | $2.3M 37663.3% | $2.4M 21825.2% | $2.0M 21896.0% | $6.3M 7075.5% | $109K 124.4% | $0 0.0% | $0 0.0% | $97K 77.7% | $260K 5418.4% | $85K |
| Selling, General & Admin | $3.8M 62725.0% | $3.2M 29447.6% | $3.6M 39559.0% | $3.9M 4451.0% | $3.0M 3378.2% | $1.2M 706.4% | $1.2M 739.1% | $1.1M 844.4% | $899K 18719.3% | $665K |
| Total Operating Expenses | $6.1M 102443.7% | $5.8M 52276.9% | $5.6M 62505.9% | $10.3M 11630.3% | $3.2M 3607.5% | $1.2M 747.0% | $1.3M 755.4% | $1.2M 939.1% | $1.2M 24471.0% | $760K |
| Operating Income | -$6.1M -102380.2% | -$5.7M -52216.9% | -$5.6M -62445.9% | -$10.2M -11562.5% | -$3.1M -3562.2% | -$1.1M -677.7% | -$1.1M -682.9% | -$1.1M -895.7% | -$1.2M -24537.6% | -$760K |
| Interest Expense | — | — | — | $0 0.0% | $4.3M 4875.5% | $1.2M 747.5% | $1.9M 1145.3% | $1.4M 1094.4% | $378K 7866.4% | $6K |
| Interest & Investment Income | — | — | $34K 377.8% | — | — | — | — | — | — | — |
| Other Income (Expense), net | $148K 2463.4% | $250K 2276.2% | $334K 3706.2% | $100K 113.2% | $22.3M 25454.9% | -$35.2M -21404.5% | -$7.4M -4443.2% | -$12.5M -10081.5% | -$1.5M -30860.5% | -$6K |
| Pretax Income | -$6.0M -99916.8% | -$5.5M -49940.7% | -$5.3M -58739.7% | -$10.1M -11449.3% | $19.2M 21892.8% | -$36.3M -22082.2% | -$8.5M -5126.1% | -$13.7M -10977.2% | -$2.7M -55398.1% | — |
| Income Tax Expense | $0 0.0% | $0 0.0% | $0 0.0% | $0 0.0% | $0 0.0% | $0 0.0% | $0 0.0% | $0 0.0% | $0 0.0% | $0 |
| Net Income | -$6.0M -99916.8% | -$5.5M -49940.7% | -$5.3M -58739.7% | -$10.1M -11449.3% | $19.2M 21892.8% | -$36.3M -22082.2% | -$8.5M -5126.1% | -$13.7M -10977.2% | -$2.7M -55398.1% | -$766K |
| Per Share | ||||||||||
| EPS (Basic) | — | — | — | -$0.93 | $7.37 | -$62.69 | — | — | — | — |
| EPS (Diluted) | -$2.52 | -$3.71 | -$3.76 | -$0.93 | $5.61 | -$62.69 | — | — | — | — |
| Weighted Avg Shares (Basic) | — | — | — | 10.9M | 2.6M | 579K | — | — | — | — |
| Weighted Avg Shares (Diluted) | 2.4M | 1.5M | 1.4M | 10.9M | 3.2M | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
EOD close · as of 2026-10-05
Where each multiple sits in its own 11-yr range · 20th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 11-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
ROE -80% against ROIC -80% — 0% of the return on equity comes from leverage and buybacks rather than from the operating business.
Equity is the year-end figure. On average equity over the two year-ends, ROE is -86.5% — the two diverge when buybacks or issuance move equity during the year.
What the company owes vs. what it holds
This shows debt/cash structure and net leverage. The year-by-year maturity schedule is on the Debt & Leverage tab.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 56.6 | 27.5 | 30.8 | 54.6 | 32.2 | 40.0 | 40.0 | 36.6 |
| Gross Profit | 43.4 | 72.5 | 69.2 | 45.4 | 67.8 | 60.0 | 60.0 | 63.4 |
| R&D | 77.7 | 0.0 | 0.0 | 124.4 | 7075.5 | 21896.0 | 21825.2 | 37663.3 |
| SG&A | 844.4 | 739.1 | 706.4 | 3378.2 | 4451.0 | 39559.0 | 29447.6 | 62725.0 |
| Operating Income | -895.7 | -682.9 | -677.7 | -3562.2 | -11562.5 | -62445.9 | -52216.9 | -102380.2 |
| Income Tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Income | -10977.2 | -5126.1 | -22082.2 | 21892.8 | -11449.3 | -58739.7 | -49940.7 | -99916.8 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on CELZ: price, valuation and headline fundamentals from SEC filings. The four questions at the top of the page are where the judgements live.
Ranked against 27 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-06-30.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | $217.9B | 28.3× | 18.5× | 5.9× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.2× | 3,070 |
| GILD | $179.3B | 21.3× | 19.7× | 6.1× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,216 |
| MRNA | $81.1B | — | — | 41.7× | -39.9% | 55.3% | -145% | -32.6% | -30.5% | — | 774 |
| BIIB | $33.0B | 25.4× | 14.9× | 3.3× | 2.2% | 75.7% | 13.1% | 7.1% | 5.3% | 2.4× | 1,010 |
| NBIX | $14.7B | 30.9× | 21.6× | 5.1× | 21.4% | 98.2% | 16.7% | 14.7% | 14.7% | -1.1× | 747 |
| EXEL | $14.6B | 21.2× | 15.6× | 6.3× | 7.0% | 96.4% | 33.7% | 36.2% | 36.2% | -0.5× | 722 |
| TWST | $13.6B | — | — | 36.1× | 20.3% | 50.7% | -20.6% | -16.4% | -16.4% | — | 322 |
| HALO | $12.3B | 42.3× | 29.8× | 8.8× | 37.6% | 83.6% | 22.7% | 649% | 14.5% | 4.2× | 640 |
| TECH | $11.4B | 62.6× | 31.8× | 9.4× | -0.4% | 65.8% | 15.0% | 8.6% | 8.6% | -0.8× | 572 |
| RGEN | $10.7B | 220.3× | 112.5× | 14.5× | 16.4% | 52.3% | 6.6% | 2.3% | 1.8% | -0.3× | 465 |
| KRYS | $9.9B | 49.0× | 56.4× | 25.5× | 33.9% | — | 52.6% | 16.8% | 16.8% | -3.0× | 409 |
| QGEN | $9.5B | 23.6× | 15.6× | 4.5× | 5.7% | 62.2% | 20.3% | 11.2% | 7.8% | 1.2× | — |
| IOVA | $6.4B | — | — | 24.3× | 60.6% | 34.3% | -148% | -56.0% | -56.0% | — | 288 |
| ADPT | $4.8B | — | — | 17.2× | 54.8% | 74.2% | -21.5% | -27.2% | -17.0% | — | 283 |
| RXRX | $2.6B | — | — | 34.3× | 26.9% | 5.0% | -863% | -57.0% | -56.1% | — | 341 |
| ADMA | $2.3B | 16.9× | 11.3× | 4.4× | 19.6% | 57.4% | 28.8% | 30.8% | 26.7% | -0.1× | 317 |
| VCEL | $2.1B | 128.3× | 88.7× | 7.6× | 16.5% | 74.4% | 6.0% | 4.7% | 4.7% | -4.4× | 307 |
| NVAX | $2.1B | 4.9× | 4.3× | 1.8× | 64.7% | 93.5% | 39.2% | -345% | 378% | 0.0× | 263 |
| BCRX | $2.1B | 6.7× | 5.8× | 2.4× | 94.1% | 97.8% | 30.2% | -221% | -221% | -0.3× | 312 |
| VIR | $2.0B | — | — | 29.1× | -7.6% | 100.0% | -639% | -57.2% | -57.2% | — | 233 |
| IMCR | $1.5B | — | — | 3.8× | 29.0% | 98.7% | -8.9% | -9.3% | -9.3% | — | 132 |
| AUTL | $487M | — | — | 6.5× | 645% | -27.8% | -381% | -161% | -161% | — | 82 |
| CGEN | $219M | 6.1× | 4.0× | 3.0× | 161% | 87.3% | 48.6% | 34.4% | 34.4% | -2.9× | 83 |
| PLX | $218M | — | — | 4.1× | -1.2% | 48.8% | -12.5% | -13.7% | -13.7% | — | 103 |
| CHRS | $173M | 0.8× | — | 4.1× | 59.8% | 67.2% | — | 275% | 275% | — | 147 |
| CELZ | $7M | — | — | — | -45.5% | 63.4% | — | -79.8% | -79.8% | — | 13 |
Peers = companies sharing CELZ's sector (Biological Products, (No Diagnostic Substances)) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
No positive operating income in the last three years, so there is no return on capital to compare against its cost.
| Fiscal year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY2017 | -66.7% | -24537.6% | -55398.1% |
| FY2018 | 43.4% | -895.7% | -10977.2% |
| FY2019 | 72.5% | -682.9% | -5126.1% |
| FY2020 | 69.2% | -677.7% | -22082.2% |
| FY2021 | 45.4% | -3562.2% | 21892.8% |
| FY2022 | 67.8% | -11562.5% | -11449.3% |
| FY2023 | 60.0% | -62445.9% | -58739.7% |
| FY2024 | 60.0% | -52216.9% | -49940.7% |
| FY2025 | 63.4% | -102380.2% | -99916.8% |
Return on equity (-80%) and return on invested capital (-80%) are within a couple of points in FY2025, so the headline return is the operating return — there is no meaningful leverage effect to strip out.
No material counter-signal in the checked set: ROIC vs WACC spread, 5-year spread history, gross margin trend, operating margin trend, net margin against 3 years ago, revenue growth, ROIC ex-goodwill gap.
Missing from our data, so excluded from this answer: positive EBIT.
Fewer than three profitable years with a cash flow statement, so cash conversion cannot be judged.
No material counter-signal in the checked set: FCF / net income over 3 and 5 years, Sloan accruals, SBC as a share of revenue, SBC as a share of operating cash flow, SBC-adjusted free cash flow, free cash flow per diluted share, buybacks against SBC issued, capex vs depreciation, free cash flow against revenue, share count since the first year on file, cash conversion cycle (DSO, DIO, DPO), receivables growth against revenue growth.
Missing from our data, so excluded from this answer: 3 years of cash flow.
No debt, so there is no leverage path to distress.
This schedule comes from a filing dated 2017-12-31, 3201 days old. Maturities are shown relative to that date, not to today.
Ladder as of 2017-12-31 (10-K); cash from the 2017-12-31 balance sheet; FCF from FY2017. Free cash flow is negative, so projected resources fall rather than accumulate.
Balance sheet at 2017-12-31. Undrawn revolving credit is not shown: the tag is collected but not yet mapped through to the API.
Cash burn, not leverage, is the risk for a debt-free company — see question 2 for cash conversion.
No positive free cash flow to discount, so the price cannot be expressed as a growth requirement.
No material counter-signal in the checked set: reverse-DCF implied growth, historical FCF CAGR, per-year FCF growth distribution, reporting-basis breaks, discount rate used, free-cash-flow basis (stock comp charged?).
Missing from our data, so excluded from this answer: free_cash_flow.